Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma

Purpose To evaluate survival and ocular outcome in recurrent uveal melanoma treated with proton beam therapy as salvage therapy. Design Retrospective, interventional case series. Methods We evaluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherapy, tran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of ophthalmology 2014-11, Vol.158 (5), p.948-956
Hauptverfasser: Riechardt, Aline I, Cordini, Dino, Dobner, Bianca, Seibel, Ira, Gundlach, Enken, Rehak, Matus, Hager, Annette, Stark, Roland, Moser, Lutz, Joussen, Antonia M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 956
container_issue 5
container_start_page 948
container_title American journal of ophthalmology
container_volume 158
creator Riechardt, Aline I
Cordini, Dino
Dobner, Bianca
Seibel, Ira
Gundlach, Enken
Rehak, Matus
Hager, Annette
Stark, Roland
Moser, Lutz
Joussen, Antonia M
description Purpose To evaluate survival and ocular outcome in recurrent uveal melanoma treated with proton beam therapy as salvage therapy. Design Retrospective, interventional case series. Methods We evaluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic therapy. All patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between July 2000 and December 2010. Kaplan-Meier analysis was used to obtain survival rates. Results The Kaplan-Meier estimator for local tumor control was 92.1% at 10 years after secondary treatment with proton beam therapy. Local recurrence developed in 3 patients; 1 of them underwent enucleation. During follow-up, 20.8% of the patients died (16.7% of metastasis, 4.1% of other causes or not specified). The most frequent surgical interventions were phacoemulsification (20.8%) and pars plana vitrectomy (10.4%). The Kaplan-Meier estimators were 77.4% for survival and 70.1% for the absence of metastasis 10 years after the primary treatment. Conclusions Proton beam therapy as a salvage treatment resulted in high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was transpupillary thermotherapy or plaque brachytherapy. Preservation of the globe was possible in most patients. Enucleations were indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complications like intractable pain or secondary glaucoma. Retreatment was associated with vision deterioration, but loss of vision remained exceptional. Further larger prospective studies are needed to confirm the presented results of our retrospective analysis.
doi_str_mv 10.1016/j.ajo.2014.07.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629953272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002939414004048</els_id><sourcerecordid>1629953272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-41a8e1b22ec6d93cbe9720a4c9dee39708ff226d7c0386d467898ada3a1081c63</originalsourceid><addsrcrecordid>eNp9kU1rFEEQhhtRzBr9AV5kwIuXGas_tj8QAxrUBFYUk5yb3p5a7XFmeu2eWdh_by8bI-SQU1Hw1EvVU4S8pNBQoPJt17guNgyoaEA1QPkjsqBamZpqQx-TBQCw2nAjTsiznLvSSiXUU3LClsA1Z2pB3l-5fud-YvU9xSmO1Ud0Q3X9C5Pb7qswVqvoXV_9QD-nhONU3eyw9F-xd2Mc3HPyZOP6jC9u6ym5-fzp-vyiXn37cnn-YVX7JcipFtRppGvG0MvWcL9Goxg44U2LyI0CvdkwJlvly1qyFVJpo13ruKOgqZf8lLw55m5T_DNjnuwQsse-bIFxzpZKZsyyHMQK-voe2sU5jWW7QlEhmCyRhaJHyqeYc8KN3aYwuLS3FOzBre1scWsPbi0oW9yWmVe3yfN6wPZu4p_MArw7AlhU7AImm33A0WMbEvrJtjE8GH92b9r3YQxF_2_cY_5_hc3Mgr06PPfwWyoABAjN_wL6B5vg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1614426081</pqid></control><display><type>article</type><title>Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Riechardt, Aline I ; Cordini, Dino ; Dobner, Bianca ; Seibel, Ira ; Gundlach, Enken ; Rehak, Matus ; Hager, Annette ; Stark, Roland ; Moser, Lutz ; Joussen, Antonia M</creator><creatorcontrib>Riechardt, Aline I ; Cordini, Dino ; Dobner, Bianca ; Seibel, Ira ; Gundlach, Enken ; Rehak, Matus ; Hager, Annette ; Stark, Roland ; Moser, Lutz ; Joussen, Antonia M</creatorcontrib><description>Purpose To evaluate survival and ocular outcome in recurrent uveal melanoma treated with proton beam therapy as salvage therapy. Design Retrospective, interventional case series. Methods We evaluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic therapy. All patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between July 2000 and December 2010. Kaplan-Meier analysis was used to obtain survival rates. Results The Kaplan-Meier estimator for local tumor control was 92.1% at 10 years after secondary treatment with proton beam therapy. Local recurrence developed in 3 patients; 1 of them underwent enucleation. During follow-up, 20.8% of the patients died (16.7% of metastasis, 4.1% of other causes or not specified). The most frequent surgical interventions were phacoemulsification (20.8%) and pars plana vitrectomy (10.4%). The Kaplan-Meier estimators were 77.4% for survival and 70.1% for the absence of metastasis 10 years after the primary treatment. Conclusions Proton beam therapy as a salvage treatment resulted in high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was transpupillary thermotherapy or plaque brachytherapy. Preservation of the globe was possible in most patients. Enucleations were indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complications like intractable pain or secondary glaucoma. Retreatment was associated with vision deterioration, but loss of vision remained exceptional. Further larger prospective studies are needed to confirm the presented results of our retrospective analysis.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2014.07.013</identifier><identifier>PMID: 25038327</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Charged particles ; Coagulation ; Female ; Follow-Up Studies ; Germany - epidemiology ; Humans ; Lasers ; Male ; Melanoma ; Melanoma - diagnosis ; Melanoma - mortality ; Melanoma - radiotherapy ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - radiotherapy ; Ophthalmology ; Patients ; Photodynamic therapy ; Proton Therapy - methods ; Radiation therapy ; Retrospective Studies ; Salvage ; Salvage Therapy - methods ; Studies ; Survival Rate - trends ; Tumors ; Uveal Neoplasms - diagnosis ; Uveal Neoplasms - mortality ; Uveal Neoplasms - radiotherapy</subject><ispartof>American journal of ophthalmology, 2014-11, Vol.158 (5), p.948-956</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Nov 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-41a8e1b22ec6d93cbe9720a4c9dee39708ff226d7c0386d467898ada3a1081c63</citedby><cites>FETCH-LOGICAL-c506t-41a8e1b22ec6d93cbe9720a4c9dee39708ff226d7c0386d467898ada3a1081c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajo.2014.07.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25038327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riechardt, Aline I</creatorcontrib><creatorcontrib>Cordini, Dino</creatorcontrib><creatorcontrib>Dobner, Bianca</creatorcontrib><creatorcontrib>Seibel, Ira</creatorcontrib><creatorcontrib>Gundlach, Enken</creatorcontrib><creatorcontrib>Rehak, Matus</creatorcontrib><creatorcontrib>Hager, Annette</creatorcontrib><creatorcontrib>Stark, Roland</creatorcontrib><creatorcontrib>Moser, Lutz</creatorcontrib><creatorcontrib>Joussen, Antonia M</creatorcontrib><title>Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Purpose To evaluate survival and ocular outcome in recurrent uveal melanoma treated with proton beam therapy as salvage therapy. Design Retrospective, interventional case series. Methods We evaluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic therapy. All patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between July 2000 and December 2010. Kaplan-Meier analysis was used to obtain survival rates. Results The Kaplan-Meier estimator for local tumor control was 92.1% at 10 years after secondary treatment with proton beam therapy. Local recurrence developed in 3 patients; 1 of them underwent enucleation. During follow-up, 20.8% of the patients died (16.7% of metastasis, 4.1% of other causes or not specified). The most frequent surgical interventions were phacoemulsification (20.8%) and pars plana vitrectomy (10.4%). The Kaplan-Meier estimators were 77.4% for survival and 70.1% for the absence of metastasis 10 years after the primary treatment. Conclusions Proton beam therapy as a salvage treatment resulted in high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was transpupillary thermotherapy or plaque brachytherapy. Preservation of the globe was possible in most patients. Enucleations were indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complications like intractable pain or secondary glaucoma. Retreatment was associated with vision deterioration, but loss of vision remained exceptional. Further larger prospective studies are needed to confirm the presented results of our retrospective analysis.</description><subject>Charged particles</subject><subject>Coagulation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Germany - epidemiology</subject><subject>Humans</subject><subject>Lasers</subject><subject>Male</subject><subject>Melanoma</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - mortality</subject><subject>Melanoma - radiotherapy</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - radiotherapy</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Photodynamic therapy</subject><subject>Proton Therapy - methods</subject><subject>Radiation therapy</subject><subject>Retrospective Studies</subject><subject>Salvage</subject><subject>Salvage Therapy - methods</subject><subject>Studies</subject><subject>Survival Rate - trends</subject><subject>Tumors</subject><subject>Uveal Neoplasms - diagnosis</subject><subject>Uveal Neoplasms - mortality</subject><subject>Uveal Neoplasms - radiotherapy</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1rFEEQhhtRzBr9AV5kwIuXGas_tj8QAxrUBFYUk5yb3p5a7XFmeu2eWdh_by8bI-SQU1Hw1EvVU4S8pNBQoPJt17guNgyoaEA1QPkjsqBamZpqQx-TBQCw2nAjTsiznLvSSiXUU3LClsA1Z2pB3l-5fud-YvU9xSmO1Ud0Q3X9C5Pb7qswVqvoXV_9QD-nhONU3eyw9F-xd2Mc3HPyZOP6jC9u6ym5-fzp-vyiXn37cnn-YVX7JcipFtRppGvG0MvWcL9Goxg44U2LyI0CvdkwJlvly1qyFVJpo13ruKOgqZf8lLw55m5T_DNjnuwQsse-bIFxzpZKZsyyHMQK-voe2sU5jWW7QlEhmCyRhaJHyqeYc8KN3aYwuLS3FOzBre1scWsPbi0oW9yWmVe3yfN6wPZu4p_MArw7AlhU7AImm33A0WMbEvrJtjE8GH92b9r3YQxF_2_cY_5_hc3Mgr06PPfwWyoABAjN_wL6B5vg</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Riechardt, Aline I</creator><creator>Cordini, Dino</creator><creator>Dobner, Bianca</creator><creator>Seibel, Ira</creator><creator>Gundlach, Enken</creator><creator>Rehak, Matus</creator><creator>Hager, Annette</creator><creator>Stark, Roland</creator><creator>Moser, Lutz</creator><creator>Joussen, Antonia M</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma</title><author>Riechardt, Aline I ; Cordini, Dino ; Dobner, Bianca ; Seibel, Ira ; Gundlach, Enken ; Rehak, Matus ; Hager, Annette ; Stark, Roland ; Moser, Lutz ; Joussen, Antonia M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-41a8e1b22ec6d93cbe9720a4c9dee39708ff226d7c0386d467898ada3a1081c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Charged particles</topic><topic>Coagulation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Germany - epidemiology</topic><topic>Humans</topic><topic>Lasers</topic><topic>Male</topic><topic>Melanoma</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - mortality</topic><topic>Melanoma - radiotherapy</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - radiotherapy</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Photodynamic therapy</topic><topic>Proton Therapy - methods</topic><topic>Radiation therapy</topic><topic>Retrospective Studies</topic><topic>Salvage</topic><topic>Salvage Therapy - methods</topic><topic>Studies</topic><topic>Survival Rate - trends</topic><topic>Tumors</topic><topic>Uveal Neoplasms - diagnosis</topic><topic>Uveal Neoplasms - mortality</topic><topic>Uveal Neoplasms - radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riechardt, Aline I</creatorcontrib><creatorcontrib>Cordini, Dino</creatorcontrib><creatorcontrib>Dobner, Bianca</creatorcontrib><creatorcontrib>Seibel, Ira</creatorcontrib><creatorcontrib>Gundlach, Enken</creatorcontrib><creatorcontrib>Rehak, Matus</creatorcontrib><creatorcontrib>Hager, Annette</creatorcontrib><creatorcontrib>Stark, Roland</creatorcontrib><creatorcontrib>Moser, Lutz</creatorcontrib><creatorcontrib>Joussen, Antonia M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riechardt, Aline I</au><au>Cordini, Dino</au><au>Dobner, Bianca</au><au>Seibel, Ira</au><au>Gundlach, Enken</au><au>Rehak, Matus</au><au>Hager, Annette</au><au>Stark, Roland</au><au>Moser, Lutz</au><au>Joussen, Antonia M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>158</volume><issue>5</issue><spage>948</spage><epage>956</epage><pages>948-956</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>Purpose To evaluate survival and ocular outcome in recurrent uveal melanoma treated with proton beam therapy as salvage therapy. Design Retrospective, interventional case series. Methods We evaluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam therapy, laser photocoagulation, CyberKnife radiation, or photodynamic therapy. All patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between July 2000 and December 2010. Kaplan-Meier analysis was used to obtain survival rates. Results The Kaplan-Meier estimator for local tumor control was 92.1% at 10 years after secondary treatment with proton beam therapy. Local recurrence developed in 3 patients; 1 of them underwent enucleation. During follow-up, 20.8% of the patients died (16.7% of metastasis, 4.1% of other causes or not specified). The most frequent surgical interventions were phacoemulsification (20.8%) and pars plana vitrectomy (10.4%). The Kaplan-Meier estimators were 77.4% for survival and 70.1% for the absence of metastasis 10 years after the primary treatment. Conclusions Proton beam therapy as a salvage treatment resulted in high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was transpupillary thermotherapy or plaque brachytherapy. Preservation of the globe was possible in most patients. Enucleations were indicated only in case of re-recurrences of uveal melanoma, but not because of secondary complications like intractable pain or secondary glaucoma. Retreatment was associated with vision deterioration, but loss of vision remained exceptional. Further larger prospective studies are needed to confirm the presented results of our retrospective analysis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25038327</pmid><doi>10.1016/j.ajo.2014.07.013</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9394
ispartof American journal of ophthalmology, 2014-11, Vol.158 (5), p.948-956
issn 0002-9394
1879-1891
language eng
recordid cdi_proquest_miscellaneous_1629953272
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Charged particles
Coagulation
Female
Follow-Up Studies
Germany - epidemiology
Humans
Lasers
Male
Melanoma
Melanoma - diagnosis
Melanoma - mortality
Melanoma - radiotherapy
Middle Aged
Neoplasm Recurrence, Local - diagnosis
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - radiotherapy
Ophthalmology
Patients
Photodynamic therapy
Proton Therapy - methods
Radiation therapy
Retrospective Studies
Salvage
Salvage Therapy - methods
Studies
Survival Rate - trends
Tumors
Uveal Neoplasms - diagnosis
Uveal Neoplasms - mortality
Uveal Neoplasms - radiotherapy
title Salvage Proton Beam Therapy in Local Recurrent Uveal Melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A26%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Salvage%20Proton%20Beam%20Therapy%20in%20Local%20Recurrent%20Uveal%20Melanoma&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Riechardt,%20Aline%20I&rft.date=2014-11-01&rft.volume=158&rft.issue=5&rft.spage=948&rft.epage=956&rft.pages=948-956&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2014.07.013&rft_dat=%3Cproquest_cross%3E1629953272%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1614426081&rft_id=info:pmid/25038327&rft_els_id=1_s2_0_S0002939414004048&rfr_iscdi=true